⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
THE SKIN OF COLOR SOCIETY (SOCS) SUCCESSFULLY PRESENTS LANDMARK SYMPOSIUM CHAMPIONING EVIDENCE-BASED DERMATOLOGY AND COLLABORATION
prnewswire.com
ABBV
JNJ
ARQT
BMY
LLY
INCY
SNY
REGN
PFE
UCB
BIIB
ORGN
TAK
ELMD
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
businesswire.com
INCY
Immune Checkpoint Inhibitors Market Report 2026-2030 with Detailed Company Profiles, Grant Analyses, Partnership Evaluations and More
globenewswire.com
BMY
GSK
INCY
NVS
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
JNJ
PFE
ABBV
LLY
AMGN
INCY
GILD
BHC
AZN
SUN
Zynyz (Incyte: retifanlimab-dlwr) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
INCY
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
globenewswire.com
ARQT
PVLA
INCY
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
globenewswire.com
ADAG
INCY
Form 8-K
sec.gov
INCY
Incyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD)
businesswire.com
INCY
Incyte annuncia gli ultimi nuovi dati positivi ottenuti in 54 settimane su povorcitinib nell'idrosadenite suppurativa al Meeting annuale 2026 della American Academy of Dermatology (AAD)
businesswire.com
INCY